Semaglutide is a prescription medication in the GLP-1 receptor agonist class, developed by Novo Nordisk and approved by the FDA under three brand names: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. The molecule imitates a natural gut hormone, and a structural change that lets one dose last about a week is what puts the injectable forms on a once-weekly schedule. The human clinical record is the strong end of the evidence spectrum here, with trials showing major blood sugar improvements, average weight loss near fifteen percent of body weight in obesity treatment, and a measured reduction in cardiovascular events for certain high-risk patients.
Semaglutide is an FDA-approved GLP-1 receptor agonist sold as Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management, producing about fifteen percent average body-weight loss in obesity trials.
The mechanism is well documented in human pharmacology: semaglutide copies glucagon-like peptide-1, the hormone the gut releases after eating to manage blood sugar and signal fullness. Natural GLP-1 is broken down within minutes by the enzyme DPP-4, so the molecule is engineered to resist that breakdown and to bind albumin in the blood, which together stretch its activity to roughly a week per dose.
Semaglutide stimulates insulin only when blood glucose is high, suppresses glucagon, slows gastric emptying, and acts on brain appetite centers, combining to steady blood sugar and cut calorie intake.
The approved uses cluster around three areas, and the brand a patient receives signals which one applies. The injectable Ozempic and oral Rybelsus are approved for blood sugar control in adults with type 2 diabetes, Wegovy is approved for chronic weight management in patients meeting set body-mass criteria, and the FDA has also cleared semaglutide to reduce major cardiovascular events in adults with established cardiovascular disease alongside diabetes or obesity.
Semaglutide holds FDA approvals for type 2 diabetes, chronic weight management at a BMI of thirty or higher (or twenty-seven with a related condition), and cardiovascular risk reduction, but is not approved for type 1 diabetes and is not a substitute for insulin.
The same molecule reaches the market as three distinct Novo Nordisk products, and the difference between them is indication and delivery rather than chemistry. The most common point of confusion is compounded semaglutide, which pharmacies produced in volume during the brand shortage; the published regulatory position is that compounded versions are not FDA-approved, are not tested to the same quality and consistency standard, and have become harder to obtain legally as the official shortage resolved.
| Brand | Form | Approved use | Dose range |
|---|---|---|---|
| Ozempic | Once-weekly injection | Type 2 diabetes | 0.25 mg up to 2 mg |
| Wegovy | Once-weekly injection | Chronic weight management | up to 2.4 mg |
| Rybelsus | Daily oral tablet | Type 2 diabetes | 3, 7, 14 mg |
Semaglutide is sold as Ozempic, Wegovy, and Rybelsus, with no FDA-approved generic, while compounded semaglutide is not FDA-approved and carries quality and consistency uncertainty the brand products do not.
The defining feature of the documented dosing schedule is slow, stepwise escalation rather than a single effective dose from the start. The published protocols start the injectable forms low, often 0.25 milligrams for the diabetes form, a level meant to let the body adjust and limit nausea rather than to be fully effective, then raise the dose at roughly four-week intervals until the maintenance target is reached.
Injectable semaglutide is documented as a once-weekly subcutaneous dose escalated about every four weeks to a 1 to 2.4 mg maintenance level, while the oral tablet requires an empty stomach and a thirty-minute wait before anything else.
The documented results fall into three measurable areas, and the human clinical evidence behind them is the strongest tier of data. The obesity trials behind Wegovy reported adults losing on average about fifteen percent of starting body weight over roughly sixteen months at the 2.4 milligram dose, a magnitude well beyond most earlier weight-loss medications, though individual results vary widely.
Wegovy obesity trials reported roughly fifteen percent average body-weight loss and outcome trials documented reduced major cardiovascular events, but the benefits depend on continued treatment and tend to reverse once the drug is stopped.
The published safety record is dominated by gastrointestinal effects that stem directly from slowed digestion, with nausea the most common, followed by vomiting, diarrhea, constipation, abdominal pain, and indigestion. These are usually mild to moderate, appear most strongly during dose increases, and tend to fade as the body adjusts, which is the reason the dose is escalated slowly rather than started high. The serious risks are rarer but carry the strongest regulatory weight.
Semaglutide carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies, alongside documented associations with acute pancreatitis, gallbladder disease, and kidney injury, on top of common but usually transient gastrointestinal effects.
The labeling draws firm contraindication boundaries, the clearest being a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, both tied to the thyroid tumor signal from animal studies, plus any known serious allergic reaction to the drug. Pregnancy is a separate boundary the record treats seriously: semaglutide is not recommended during pregnancy because weight loss offers no benefit to a developing baby and animal data raised concerns, so it is generally stopped at least two months before a planned pregnancy.
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 and is not recommended in pregnancy, with documented cautions for pancreatitis history, severe gastrointestinal disease, and concurrent insulin or sulfonylurea use.
Within the GLP-1 class, the published comparative data places semaglutide near the top for potency but no longer alone at the summit. Its closest documented competitor is tirzepatide, sold as Mounjaro and Zepbound, which acts on two gut-hormone receptors rather than one; trial data generally show tirzepatide producing somewhat greater average weight loss, on the order of twenty percent at the highest doses, against roughly fifteen percent for semaglutide.
| Drug | Class / target | Weight effect | Dosing |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~15% at high dose | once weekly (or daily oral) |
| Tirzepatide | GLP-1 and GIP | ~20% at high dose | once weekly |
| Liraglutide | GLP-1 only | less than semaglutide | once daily |
| Metformin | Biguanide pill | minimal | daily, low cost |
Trial data place semaglutide around fifteen percent average weight loss against tirzepatide's roughly twenty percent, ahead of once-daily liraglutide and far more powerful than low-cost metformin, with the right choice resting on the treatment goal, cost, and tolerance.
The cost reality is the sharpest practical barrier, with list prices for the injectable forms commonly around one thousand dollars or more for a month's supply before insurance or discounts. What a patient actually pays splits sharply by indication: many plans cover semaglutide for type 2 diabetes at a manageable copay, while far fewer cover it for weight loss alone, and Medicare has historically been barred from covering medications used solely for obesity, though that landscape is shifting.
Brand-name injectable semaglutide commonly lists around one thousand dollars or more per month, with insurance often covering the diabetes indication but far less often covering weight loss, which is what drove the surge in cheaper but non-FDA-approved compounded versions.
The documented pattern after discontinuation is reversal, because the drug manages ongoing conditions rather than curing them. The clearest example is weight: studies that followed patients after they stopped found roughly two-thirds of lost weight regained within about a year in one major trial, as appetite returns and the metabolic drivers of weight gain reassert themselves, while blood sugar drifts back toward pretreatment levels in people with type 2 diabetes.
Discontinuation studies documented roughly two-thirds of lost weight regained within about a year with no chemical withdrawal syndrome, which is why clinicians increasingly frame semaglutide as a long-term therapy for chronic conditions rather than a short course.
Educational use only. This article describes what the published scientific and clinical literature reports about Semaglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
